High-level expression, purification and characterization of codon-optimized recombinant hemagglutinin 5 proteins in mammalian cells

Chinese Medical Journal

Volumn 123, Issue 8, 2010, Pages 1073-1077

  Yang, Jing Lin ^a   Wang, Hong Liang ^a   Wang, Shun Xin ^a   Yang, Peng ^a   Liu, Kang Tai ^a   Jiang, Cheng Yu ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

Avian influenza; Hemagglutinin; Mammalian cell expression; Protein purification

Indexed keywords

GLYCOPROTEIN; HEMAGGLUTININ; HEMAGGLUTININ 5 IMMUNOGLOBULIN FC FRAGMENT FUSION PROTEIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CODON; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ACTIVATED CELL SORTER; IMMUNOGLOBULIN STRUCTURE; MAMMAL CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PROCESS OPTIMIZATION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; PROTEIN PURIFICATION; RECOMBINANT GENE; SOLUBILITY; VACCINE PRODUCTION; WESTERN BLOTTING;

CELL LINE; CODON; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; PROTEIN FOLDING; RECOMBINANT PROTEINS;

EID: 77951236719     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2010.08.018     Document Type: Article

References (22)

1. Horimoto T, Kawaoka Y. Influenza: lessons from past pandemics, warnings from current incidents. Nat Rev Microbiol 2005; 3: 591-600.
2. Gambotto A, Barratt-Boyes SM, de Jong MD, Neumann G, Kawaoka Y. Human infection with highly pathogenic H5N1 influenza virus. Lancet 2008; 371: 1464-1475.
3. Skehel JJ, Wiley DC. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Ann Rev Biochem 2000; 69: 531-569.
4. Doherty PC, Turner SJ, Webby RG, Thomas PG. Influenza and the challenge for immunology. Nat Immunol 2006; 7: 449-455.
5. Stephenson I, Nicholson KG, Wood JM, Zambon MC, Katz JM. Confronting the avian influenza threat: vaccine development for a potential pandemic. Lancet Infect Dis 2004; 4: 499-509.
6. Wang K, Holtz KM, Anderson K, Chubet R, Mahmoud W, Cox MM. Expression and purification of an influenza hemagglutinin-one step closer to a recombinant protein-based influenza vaccine. Vaccine 2006; 24: 2176-2185.
7. Crawford J, Wilkinson B, Vosnesensky A, Smith G, Garcia M, Stone H, et al. Baculovirus-derived hemagglutinin vaccines protect against lethal influenza infections by avian H5 and H7 subtypes. Vaccine 1999; 17: 2265-2274.
8. Ito T, Kawaoka Y. Host-range barrier of influenza A viruses. Vet Microbiol 2000; 74: 71-75.
9. White J, Kartenbeck J, Helenius A. Membrane fusion activity of influenza virus. EMBO J 1982; 1: 217-222.
10. Possee RD. Cell-surface expression of influenza virus haemagglutinin in insect cells using a baculovirus vector. Virus Res 1986; 5: 43-59
11. Hartshorn KL, Webby R, White MR, Tecle T, Pan C, Boucher S, et al. Role of viral hemagglutinin glycosylation in anti-influenza activities of recombinant surfactant protein D. Respir Res 2008; 9: 65.
12. Skehel JJ, Stevens DJ, Daniels RS, Douglas AR, Knossow M, Wilson IA, et al. A carbohydrate side chain on hemagglutinins of Hong Kong influenza viruses inhibits recognition by a monoclonal antibody. Proc Natl Acad Sci U S A 1984; 81: 1779-1783.
13. Bright RA, Ross TM, Subbarao K, Robinson HL, Katz JM. Impact of glycosylation on the immunogenicity of a DNA-based influenza H5 HA vaccine. Virology 2003; 308: 270-278.
14. Haas J, Park EC, Seed B. Codon usage limitation in the expression of HIV-1 envelope glycoprotein. Curr Biol 1996; 6: 315-324
15. Wang H, Jiang C. Influenza A virus H5N1 entry into host cells is through clathrin-dependent endocytosis. Sci China C Life Sci 2009; 52: 464-469
16. Wang H, Jiang C. Avian influenza H5N1: an update on molecular pathogenesis. Sci China C Life Sci 2009; 52: 459-463
17. Lu CY, Lu JH, Chen WQ, Jiang LF, Tan BY, Ling WH, et al. Potential infections of H5N1 and H9N2 avian influenza do exist in Guangdong populations of China. Chin Med J 2008; 121: 2050-2053.
18. Qin CF, Qin ED. Seasonal influenza vaccination may mitigate the potential impact of an H5N1 pandemic. Chin Med J 2008; 121: 1481-1483.
19. + memory B cells. PLoS ONE 2008; 3: e3942.
20. Altiok E, Taylan F, Yenen OS, Demirkeser G, Bozaci M, Onel D, et al. Mutations in influenza A virus (H5N1) and possible limited spread, Turkey, 2006. Emerg Infect Dis 2008; 14: 491-492.
21. Sugrue RJ. Viruses and glycosylation: an overview. Methods Mol Biol 2007; 379: 1-13.
22. Wurm FM. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotechnol 2004; 22: 1393-1398.